Skin Cancer | Topics

The complexity of carcinosarcoma
December 21, 2021

Sunil A. Reddy, MD gives his perspective on the article, Metastatic Basal Cell (BCC) Arising from a Primary Cutaneous Carcinosarcoma.

Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma
December 20, 2021

This study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.

Duration of Treatment for Melanoma
November 02, 2021

John Kirkwood, MD, PhD, gives his opinion on duration of treatment for patients with melanoma.

Taking Drug Holidays Amidst Melanoma Therapy
November 02, 2021

Dr John Kirkwood explores the idea of taking drug holidays during melanoma treatment and whether it is helpful or harmful.

How the Emergence of Immunotherapy has Impacted Practice Patterns for Treatment and Management of Merkel Cell Carcinoma
October 19, 2021

A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.

Cemiplimab Shows Clinical Benefit for BCC After Hedgehog Inhibitor Therapy
July 31, 2021

Cemiplimab for patients with either metastatic or locally advanced basal cell carcinoma showed antitumor activity in a phase 2 trial.

FDA Expands Indication for Pembrolizumab in Locally Advanced CSCC
July 06, 2021

Pembrolizumab has been granted an expanded indication by the FDA for locally advanced cutaneous squamous cell carcinoma.

Pembrolizumab Induces Robust, Durable Antitumor Activity in Advanced CSCC
April 11, 2021

These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma
February 11, 2021

First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.

FDA Approves Cemiplimab as First Immunotherapy to Treat Patients With Advanced BCC
February 09, 2021

The PD-1 inhibitor cemiplimab was granted approval in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom these therapies are not appropriate.